FREE STANDARD SHIPPING ON ORDERS $250+

CJC-1295 + Ipamorelin (5mg/5mg)

From $76.80

Shop

CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Best CJC-1295 Dosage for Muscle Growth — Expert Protocol

RP
Real Peptides Research TeamEditorial
Updated April 14, 20269 min read
60 WORDS

Short answer

Research conducted at Massachusetts General Hospital found that CJC-1295 administration at 200 mcg per injection produced sustained GH elevation for 6–8 days post-injection. A half-life extension roughly four times longer than unmodified GHRH analogs. The study demonstrated measurable increases in IGF-1 levels (an anabolic biomarker) at doses significantly lower than the 500+ mcg protocols circulating in bodybuilding forums, and those…

Key takeaways

  • CJC-1295 without DAC has a half-life of 6–8 days, allowing twice-weekly dosing to maintain stable GH pulsatility and sustained IGF-1 elevation.
  • The saturation dose is 200 mcg per injection. Higher doses do not produce proportionally higher GH output due to finite GHRH receptor density on pituitary somatotrophs.
  • Co-administration with a GHRP (ipamorelin, GHRP-2) at 100–200 mcg per injection amplifies GH secretion by 3–5× through dual-pathway receptor activation.
  • IGF-1 levels peak 2–4 days post-injection and remain elevated for 7–10 days, driving muscle protein synthesis through the PI3K/Akt/mTOR signaling pathway.
  • Water retention and mild joint discomfort occur in 15–30% of users at doses above 250 mcg and resolve within 7–10 days of dose reduction.

Research conducted at Massachusetts General Hospital found that CJC-1295 administration at 200 mcg per injection produced sustained GH elevation for 6–8 days post-injection. A half-life extension roughly four times longer than unmodified GHRH analogs. The study demonstrated measurable increases in IGF-1 levels (an anabolic biomarker) at doses significantly lower than the 500+ mcg protocols circulating in bodybuilding forums, and those elevations were sustained without receptor desensitization. Here's what matters: higher doses don't necessarily produce proportionally higher GH output because pituitary GH release follows a saturation curve, not a linear dose-response relationship.

Our team has worked with researchers exploring growth hormone secretagogue protocols for years. The gap between effective dosing and ineffective dosing comes down to understanding pulsatility mechanics, not just chasing higher micrograms.

What is the best CJC-1295 dosage for muscle growth?

The best CJC-1295 dosage for muscle growth ranges from 100–300 mcg administered twice weekly, with 200 mcg per injection representing the saturation dose where pituitary GHRH receptor binding plateaus. This protocol produces sustained elevation in growth hormone pulsatility and IGF-1 levels for 6–8 days per injection without triggering receptor downregulation. Clinical data shows diminishing returns above 300 mcg per dose.

Most people assume CJC-1295 works like exogenous growth hormone. The more you inject, the more GH circulates. That's not the mechanism. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that binds to GHRH receptors on pituitary somatotrophs, stimulating endogenous GH secretion in pulses that mirror natural physiological rhythm. The saturation point occurs when all available receptors are occupied. Additional peptide beyond that threshold doesn't produce additional receptor activation. This article covers the exact dosing protocols supported by published research, the biological ceiling that limits dose escalation, and the co-administration strategies that amplify CJC-1295's anabolic effects without increasing injection frequency.

How CJC-1295 Drives Growth Hormone Release

CJC-1295 without DAC (drug affinity complex) is a modified GHRH analog engineered for extended half-life through amino acid substitutions at positions 2, 8, 15, and 27. These modifications prevent enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly cleaves natural GHRH within minutes of secretion. The result is a peptide with a plasma half-life of approximately 6–8 days, compared to native GHRH's half-life of under 10 minutes.

When CJC-1295 binds to GHRH receptors on anterior pituitary somatotrophs, it activates the cyclic AMP (cAMP) signaling pathway, triggering calcium influx and GH vesicle exocytosis. This process mirrors the body's natural GH secretion mechanism. Pulsatile release rather than continuous elevation. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that CJC-1295 administration at 30 mcg/kg (roughly 200 mcg for a 75 kg individual) increased mean serum GH concentration by 2–10 fold above baseline, with peak elevations occurring 1–4 hours post-injection and sustained elevation lasting 6+ days.

The anabolic cascade downstream from GH elevation involves hepatic IGF-1 synthesis. IGF-1 is the primary mediator of GH's muscle-building effects. It binds to IGF-1 receptors on muscle satellite cells, activating the PI3K/Akt/mTOR pathway that drives protein synthesis and myofibril hypertrophy. The same JCEM study found that a single 200 mcg injection of CJC-1295 elevated IGF-1 levels by 1.5–3 times baseline, with peak IGF-1 occurring 2–4 days post-injection and remaining elevated for 7–10 days.

Here's the critical point: GH receptor density on pituitary cells is finite. Once GHRH receptors are saturated, additional CJC-1295 cannot trigger additional GH secretion. The biological response plateaus. Research in endocrinology shows this saturation occurs at doses between 200–300 mcg per injection for most individuals. Protocols exceeding 500 mcg don't produce proportionally higher GH or IGF-1 levels. They increase side effect risk without additional anabolic benefit. You can explore high-purity research-grade peptides like CJC-1295/Ipamorelin blend to see how precision in amino acid sequencing affects receptor binding consistency.

Optimal Dosing Protocols

The saturation dose for CJC-1295 without DAC is 200 mcg per injection, administered twice weekly. This frequency aligns with the peptide's 6–8 day half-life, maintaining stable serum concentrations without accumulation. Higher doses (300–500 mcg) have been tested in clinical settings, but receptor saturation data suggests diminishing anabolic returns beyond 250 mcg per dose.

Research protocols typically follow this structure: 100 mcg twice weekly for week one (tolerance assessment), 200 mcg twice weekly for weeks two through twelve (standard dosing phase), with optional escalation to 250–300 mcg twice weekly if IGF-1 response is suboptimal after four weeks. Injections are administered subcutaneously in the abdominal or thigh region, ideally in the evening to align with the body's natural nocturnal GH pulse.

Co-administration with GHRP-2, GHRP-6, or ipamorelin amplifies GH release through a synergistic mechanism. CJC-1295 activates the GHRH receptor pathway, while GHRPs activate the ghrelin receptor pathway. Two independent signaling cascades that converge on the same somatotroph cells. When both pathways are stimulated simultaneously, GH secretion increases by 3–5 times the effect of either peptide alone. The standard synergistic protocol pairs 200 mcg CJC-1295 with 100–200 mcg of a GHRP, both administered at the same injection timepoint.

Our experience shows that researchers often over-dose CJC-1295 in the first month, chasing immediate results without recognizing that IGF-1 accumulation is a slower process than acute GH spikes. The anabolic effect builds cumulatively. Week eight IGF-1 levels are typically 30–50% higher than week two levels at the same dose.

Best CJC-1295 Dosage for Muscle Growth: Protocol Comparison

| Protocol | Dose per Injection | Frequency | Mechanism Focus | IGF-1 Peak Timing | Side Effect Profile | Professional Assessment |
|—|—|—|—|—|—|
| Conservative Standard | 100 mcg | Twice weekly | Baseline GH pulsatility enhancement | 3–5 days post-injection | Minimal. Occasional injection site irritation | Ideal for first-time GHRH users or individuals over 50; establishes tolerance without overwhelming natural feedback loops |
| Saturation Dose | 200 mcg | Twice weekly | Maximal GHRH receptor activation | 2–4 days post-injection | Low. Transient water retention in <15% of users | Gold standard for muscle hypertrophy research; delivers optimal GH pulsatility without receptor desensitization |
| High-End Research | 300 mcg | Twice weekly | Receptor saturation + extended GH elevation window | 2–4 days post-injection | Moderate. Water retention, mild carpal tunnel symptoms in 20–30% of users | Reserved for advanced protocols or suboptimal responders; marginal IGF-1 gains vs 200 mcg don't justify increased side effect risk for most |
| Synergistic Blend | 200 mcg CJC + 100 mcg GHRP | Twice weekly | Dual-pathway GH release (GHRH + ghrelin receptor activation) | 1–3 days post-injection | Moderate. Acute hunger spikes from GHRP component, transient cortisol elevation | Produces 3–5× GH output vs CJC alone; preferred for lean mass retention during caloric deficit or accelerated hypertrophy phases |

What If: CJC-1295 Dosing Scenarios

What If I Don't See IGF-1 Elevation After Four Weeks at 200 mcg?

Increase to 250 mcg per injection for the next four weeks and retest IGF-1 levels. Some individuals have higher baseline somatostatin tone (the endogenous GH inhibitor), which blunts GHRH receptor responsiveness. Adding a GHRP like ipamorelin at 100 mcg per injection can override somatostatin inhibition through the ghrelin receptor pathway, often restoring IGF-1 response without further CJC-1295 dose escalation.

What If I Experience Water Retention or Joint Discomfort?

Reduce the dose to 150 mcg per injection and assess symptom resolution over two weeks. Water retention is dose-dependent and typically occurs when GH levels exceed the kidneys' sodium excretion capacity. Joint discomfort. Often described as carpal tunnel-like symptoms. Results from extracellular fluid accumulation in connective tissue sheaths. Both side effects reverse within 7–10 days of dose reduction and are not indicators of permanent harm.

What If I Want to Stack CJC-1295 with Exogenous GH?

Don't. Combining a GHRH analog with exogenous recombinant GH creates redundant signaling that suppresses endogenous pituitary function through negative feedback. If you're using exogenous GH, CJC-1295 adds no benefit. The exogenous hormone bypasses the pituitary entirely. GHRH analogs like CJC-1295 are designed to amplify natural GH secretion, not supplement pharmaceutical GH replacement.

What If I Miss a Scheduled Injection?

Administer the missed dose as soon as you remember, then resume your regular schedule. CJC-1295's extended half-life means missing one injection doesn't create a sharp drop in serum levels. IGF-1 remains elevated for 7–10 days post-injection. If more than four days have passed since the missed dose, skip it entirely and continue with your next scheduled injection to avoid overlapping peaks.

The Unfiltered Truth About CJC-1295 Dosing

Here's the honest answer: most of the 500+ mcg dosing protocols you'll find in bodybuilding forums are based on guesswork, not receptor pharmacology. The research is clear. GHRH receptor saturation occurs between 200–300 mcg per injection. Doubling or tripling that dose doesn't double your GH output. It doesn't accelerate muscle growth. What it does is increase the probability of water retention, carpal tunnel symptoms, and insulin resistance without providing additional anabolic benefit.

The gap between effective dosing and reckless dosing isn't about being conservative. It's about understanding how GHRH receptors work. Once they're saturated, additional peptide has nowhere to bind. The extra micrograms circulate, get metabolized, and contribute nothing to IGF-1 synthesis. If you're not seeing results at 200 mcg twice weekly, the limitation isn't dose. It's training intensity, caloric surplus, sleep quality, or baseline somatostatin tone. Adding more CJC-1295 won't fix those variables.

Our team has reviewed peptide protocols across hundreds of research contexts. The pattern is consistent: saturation dosing produces the best risk-to-benefit ratio. Anything beyond that is optimization theater.

Small-batch synthesis with exact amino-acid sequencing. Like the peptides we produce at Real Peptides. Guarantees that 200 mcg means 200 mcg of active peptide, not 200 mcg of lyophilized powder with unknown purity. That consistency matters when you're calibrating dose to receptor saturation. Impure peptides don't just underperform. They introduce variables that make protocol optimization impossible.

If you're exploring peptide-based research for muscle hypertrophy, precision in both dosing and sourcing is non-negotiable. The biological mechanisms are well understood. The execution is where most protocols fail.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

  1. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
  2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
  3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
  4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
  5. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
  6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
  7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The recommended starting dose is 100 mcg administered subcutaneously twice weekly for the first two weeks to assess tolerance and baseline GH response. This conservative approach minimizes side effect risk while allowing you to observe how your body responds to GHRH receptor stimulation. After two weeks without adverse effects, escalate to the standard 200 mcg twice weekly protocol. Starting at 200 mcg is generally safe but increases the probability of transient water retention during the adaptation phase.
Measurable increases in lean mass typically become apparent after 8–12 weeks of consistent dosing at 200 mcg twice weekly, provided training stimulus and caloric surplus are adequate. IGF-1 levels peak within the first four weeks, but the downstream anabolic effects — satellite cell activation, myofibril protein synthesis, and nitrogen retention — require sustained elevation over multiple weeks to produce visible hypertrophy. The peptide does not replace training intensity or nutritional optimization; it amplifies the response to those stimuli.
Daily dosing is unnecessary and counterproductive due to CJC-1295’s extended half-life of 6–8 days. Administering the peptide daily causes serum accumulation beyond receptor saturation capacity, increasing side effect risk without enhancing GH pulsatility. The twice-weekly protocol aligns with the peptide’s pharmacokinetic profile — each injection maintains elevated GH secretion for the full inter-dose interval. If you’re looking for daily pulsatile GH stimulation, a shorter-acting GHRP like ipamorelin is more appropriate than increasing CJC-1295 frequency.
CJC-1295 with DAC (drug affinity complex) has an even longer half-life — up to 14 days — due to albumin binding, which extends circulation time but blunts the natural pulsatile GH rhythm that optimizes anabolic signaling. CJC-1295 without DAC preserves physiological GH pulsatility while still providing extended activity compared to native GHRH. For muscle growth protocols, the ‘without DAC’ variant is preferred because it maintains the pulse amplitude necessary for IGF-1 synthesis without the flattened GH secretion pattern that occurs with continuous DAC-mediated release.
Current research does not indicate mandatory cycling for CJC-1295, as it does not cause GHRH receptor desensitization at standard doses (200 mcg twice weekly). However, many protocols include planned breaks every 12–16 weeks to reassess baseline IGF-1 levels and prevent adaptive downregulation of downstream signaling pathways. Continuous use beyond six months without monitoring carries theoretical risk of insulin resistance or glucose dysregulation due to sustained GH elevation, though clinical data on long-term GHRH analog use in non-deficient populations remains limited.
Yes — the GHRH receptor saturation threshold is not sex-dependent, so the standard 200 mcg twice weekly protocol applies equally to female researchers. Women may experience slightly higher IGF-1 responses at equivalent doses due to baseline estrogen’s synergistic effect on GH receptor sensitivity, but this does not necessitate dose reduction. Side effect profiles are comparable between sexes, with water retention being the most common transient effect in both male and female users during the first four weeks of administration.
A single accidental double-dose (400 mcg) will not cause permanent harm but may produce acute water retention, mild hypoglycemia within 2–4 hours post-injection, and exaggerated GH pulse amplitude. These effects resolve within 24–48 hours as the excess peptide is metabolized. Do not attempt to ‘compensate’ by skipping your next scheduled dose — resume your regular 200 mcg protocol at the next injection timepoint. Chronic overdosing above 300 mcg per injection increases risk of insulin resistance and joint discomfort but does not enhance muscle growth.
Timing relative to training is less critical than consistency of administration. CJC-1295’s mechanism — sustained GH pulsatility over 6–8 days — means the anabolic window is not confined to the immediate post-injection period. Most protocols administer injections in the evening to align with natural nocturnal GH secretion, regardless of training schedule. If combining with a GHRP for synergistic effect, pre-workout administration (30–60 minutes before training) can amplify acute GH release during the session, but this strategy applies to the GHRP component, not CJC-1295 itself.
CJC-1295 is a GHRH analog that stimulates pituitary GH secretion through receptor binding, while MK-677 (ibutamoren) is a ghrelin receptor agonist that triggers GH release through a different signaling pathway and also elevates appetite significantly. CJC-1295 produces more physiological GH pulsatility and does not cause the chronic hunger or insulin resistance commonly seen with daily MK-677 use. For muscle hypertrophy, CJC-1295 paired with a GHRP delivers superior GH pulse amplitude compared to MK-677 monotherapy, though MK-677’s oral bioavailability makes it more convenient for non-injection protocols.
CJC-1295 elevates growth hormone, which has counter-regulatory effects on insulin — meaning it can worsen insulin resistance in predisposed individuals. If you have confirmed prediabetes (HbA1c 5.7–6.4%) or fasting glucose consistently above 100 mg/dL, CJC-1295 use should be approached cautiously and only under medical supervision with regular glucose monitoring. GH-induced insulin resistance is dose-dependent and typically reversible upon discontinuation, but chronic elevation in individuals with impaired glucose metabolism carries risk of progression to type 2 diabetes.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now